Related Experiment Video

Updated: Sep 28, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1

Christian M Becker1, Filip A Farnebo, Irina Iordanescu

  • 1Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA 02115, USA.

Cancer Biology & Therapy
|December 24, 2002
PubMed

Insights

Gene therapy using adenovirus encoding soluble VEGF receptor 2 (Flk1) inhibited prostate cancer growth and reduced tumor vascularity in mouse models. This approach also decreased metastasis and extended survival, offering a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Gene Therapy
  • Vascular Biology

Background:

  • Novel cancer therapies combine gene and anti-angiogenic approaches.
  • Prostate cancer treatment requires innovative strategies targeting tumor growth and metastasis.

Purpose of the Study:

  • To evaluate the efficacy of adenoviral delivery of soluble VEGF receptor 2 (Flk1) fused to an Fc domain in preclinical prostate cancer models.
  • To assess the impact of Ad Flk1-Fc on tumor growth, vascular density, metastasis, and survival.

Main Methods:

  • Adenovirus encoding soluble Flk1 receptor (Ad Flk1-Fc) was administered to SCID mice with orthotopic LNCaP tumors and TRAMP mice with spontaneous prostate tumors.
  • Tumor growth, microvessel density, lymphatic metastasis, and survival were analyzed.

Main Results:

  • Ad Flk1-Fc reduced tumor growth by 66% in LNCaP models and 42% in TRAMP models.
  • Microvessel density decreased significantly in primary tumors (68% and 40%) and lymphatic metastases.
  • A correlation was observed between reduced vascularity and decreased regional metastasis frequency, with extended survival in treated TRAMP mice.

Conclusions:

  • Adenoviral delivery of soluble Flk1 receptor is a viable strategy for reducing prostate tumor vascularity and growth.
  • This gene therapy approach demonstrates potential for inhibiting metastasis and prolonging survival in prostate cancer models.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Gene Therapy01:22

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...